Objective To assess the clinical value of MPI with ATP intervention (ATP-MPI) in the diagnosis of coronary heart disease (CHD).Methods To collect published literatures on ATP-MPI studies for the diagnosis of CHD,the PubMed,the Excerpta Medica Database (EMbase),Chinese Biomedical Literature Database (CBMdis),Vip and China National Knowledge Infrastructure (CNKI) databases were searched with computer and manual method since the data were available until to 2014.According to the inclusion and exclusion criteria,the literatures were screened to extract data by two independent evaluators.Meta-analysis was conducted with Stata 12.0 software.Results A total of 11 studies involving 968 patients were included.In patient study,which included 9 literatures and 933 patients,the Se,Sp,LR+,LRand 95％ CI of ATP-MPI diagnosis of CHD were 0.89 (0.82-0.94),0.84 (0.74-091),6.00 (3.25-9.91),0.13 (0.07-0.22),respectively.The diagnostic odds ratio (DOR) was 45.04.The AUC of summary ROC (SROC) curve was 0.94.In the coronary artery study,which included 6 literatures and 1 079 coronary arteries,the Se,Sp,LR+,LR-and 95％ CI of ATP-MPI diagnosis of coronary stenosis were 0.83 (0.71-0.91),0.92 (0.86-0.95),10.00 (5.58-16.99),0.18 (0.09-0.34),respectively.The DOR was 53.24 and the SROC AUC was 0.94.Conclusion ATP-MPI has a significant value in the diagnosis of CHD.

The early dynamic 18 F?FDG PET/CT can reflect perfusion, bio?distribution, uptake and excretion of 18 F?FDG in certain organs ( or lesions) in the early phase post injection. This imaging technique could be used to evaluate the organ ( or lesion) perfusion and to serve as a supplement for conventional 18 F?FDG PET/CT in the evaluation of glucose metabolism. This review summarizes the basic principle, imaging methods and clinical application of early dynamic 18 F?FDG PET/CT.

Objective To investigate the clinical significance of 18 F?FDG PET/CT in assessment of Tomita score in spinal metastases. Methods From October 2012 to October 2015, a total of 77 patients (38 males, 39 females;average age:56.5 years) with suspicious spinal metastasis tumors underwent 18F?FDG PET/CT scan and were included in this retrospective study. Spinal metastasis were confirmed by pa?thology. Each patient was evaluated by the scoring system of Tomita according to the grade malignancy of pri?mary lesions and metastasis of organs and bones in PET/CT. Results Seventy?two patients were osteolytic metastases. Among them, only 23 patients received operative procedure. There were 2 patients with osteoblas?tic metastases, and 3 patients with both osteolytic and osteoblastic lesions. The average Tomita score of opera?tion group was 5.7. Two to three scores were assessed in 2 patients, 4-5 scores in 9 patients, 6-7 scores in 9 patients, and 8-10 scores in 3 patients. The average score of non?operation group was 8.8. One case got 2-3 scores, 2 patients got 4-5, 18 patients got 6-7, and 33 patients got 8-10. Conclusion PET/CT is a convenient and effective tool for assessment of Tomita score in patients with spinal metastases.

Objective To evaluate the hypoxia selectivity of 99 Tcm O?labeld MAG3?nitroimidazole complexes with different spacers. Methods Four kinds of 99 Tcm O?labeled MAG3?2?nitroimidazole hypoxia imaging agents with different spacers were synthesized and radiolabeled. The stability and lipid solubility of BzMAG3?2NIEA(1), BzMAG3?2NIPA(2), BzMAG3?2NIHA(3) and BzMAG3?2NIUA(4) were measured. The uptake was investigated by biodistribution experiment using S180?bearing mice. Two?sample t test was used for statistical analysis. Results All 4 99 Tcm O?MAG3 complexes were stable and negatively charged, showing an increasing trend in fat solubility with the increase of spacer length. In biodistribution study, tumor uptake of 99TcmO?1 and 99TcmO?2 with medium? and short?carbon chain were (0.67±0.18) and (0?65±0.18) %ID/g 2 h post injection, which were (0.19±0.03) and (0.39±0.05) %ID/g for 99TcmO?3 and 99TcmO?4 with long?carbon chain (t=2.78-5.88, all P<0.05). Conclusion Molecular structure of spacers has a significant effect on the physicochemical properties and tumor targeting of 99 Tcm O?labeled MAG3?2?nitroimidazole hypoxia imaging agents, such that the medium?and short?carbon chain spacers show the best hypoxia?selective property.

Objective To prepare a novel radiolabeled FR?positive tumor targeting agent 99 Tcm?( HYNIC?NHHN?FA) ( EDDA) and evaluate its biological properties. Methods FA derivative FA?NHHN?HYNIC was synthesized and radiolabeled with 99 Tcm using EDDA as a coligand. The radiochemical purity, octanal/water partition coefficient and in vitro stabilities of the complex were studied after purified by HPLC. In vitro cellular uptakes were performed on FR?positive KB cells ( human oral epidermoid carcinoma cells) . Biodistribution and microSPECT/CT imaging were investigated on normal Kunming mice and nude mice bearing KB tumors, respectively. Results The radiochemical purity of the complex was over 95% after pu?rified by HPLC. It displayed high stability both in saline and in serum. It also exhibited high specific FR binding in FR?positive KB cells in vitro. The binding ratio was (6.76±0.60)%1 h after incubation, and de?creased to (0.24±0.02)% after adding excessive FA. The results of biodistribution showed high kidney up?take in normal mice, and the uptake reached (21.79±9.79) %ID/g 0.5 h after injection. Flank KB tumors were clearly visualized with 99 Tcm?( HYNIC?NHHN?FA ) ( EDDA ) by microSPECT/CT imaging at 2 h postinjection, and the uptake could be inhibited by excessive FA. Conclusions 99 Tcm?( HYNIC?NHHN?FA) ( EDDA) exhibits good pharmacokinetic properties, suggesting its potential as a promising FA targeting agent for tumor imaging.

Objective To investigate the capability of 99 Tcm?tricine?EDDA/HYNIC?SFSIIHTPILPL ( SP94) as a specific probe for HCC imaging. Methods HYNIC?SP94 peptide was prepared by solid phase synthesis, followed by 99 Tcm labeling with tricine?EDDA as the coligand. After determination of radiochemical purity and stability, cell binding study was carried out by incubating Huh?7 cells with 99 Tcm?tricine?EDDA/HYNIC?SP94 at different specific activities (2.5, 4.0 and 30.0 GBq/μmol). The biodistribution studies and microSPECT/CT imaging were performed in Huh?7 tumor?bearing mice ( study group) and Hela tumor?bear?ing mice ( control group ) . Statistical analysis was by two?sample t test. Results 99 Tcm?tricine?EDDA/HYNIC?SP94 was synthesized with over 95% of labeling yield, which remained stable in saline and FBS up to 12 h. With increasing concentrations of 99 Tcm?tricine?EDDA/HYNIC?SP94, Huh?7 cell binding increased but became gradually saturated. In biodistribution studies, (1.02±0.26) %ID/g of tracer was accumulated in Huh?7 tumors at 0.5 h after injection of 99 Tcm?tricine?EDDA/HYNIC?SP94, higher than that in the HYNIC?SP94 blocking group ((0.34±0.09) %ID/g;t=3.537, P<0.05). Compared to Hela tumors, Huh?7 tumors were clearly visualized by microSPECT/CT, with which better imaging quality could be achieved with higher specific radioactivity. Conclusion 99 Tcm?tricine?EDDA/HYNIC?SP94 could achieve a high labeling effi?ciency and good in vitro stability as a potential diagnostic tracer specifically targeted for HCC.